RGEN vs. AMLX
RGEN (Repligen Corporation) and AMLX (Amylyx Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — RGEN in Medical Instruments & Supplies, AMLX in Biotechnology. Over the past 3 years, RGEN returned -2.55%/yr vs -9.66%/yr for AMLX. At a 0.26 correlation, their price movements are largely independent.
Performance
RGEN vs. AMLX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RGEN achieves a -15.54% return, which is significantly lower than AMLX's 40.73% return.
RGEN
- 1D
- 9.52%
- 1M
- 20.29%
- YTD
- -15.54%
- 6M
- -16.46%
- 1Y
- 12.20%
- 3Y*
- -2.55%
- 5Y*
- -6.30%
- 10Y*
- 19.31%
AMLX
- 1D
- 3.85%
- 1M
- 25.18%
- YTD
- 40.73%
- 6M
- 36.11%
- 1Y
- 165.21%
- 3Y*
- -9.66%
- 5Y*
- —
- 10Y*
- —
RGEN vs. AMLX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
RGEN Repligen Corporation | -15.54% | 13.84% | -19.94% | 6.20% | -21.90% |
AMLX Amylyx Pharmaceuticals, Inc. | 40.73% | 219.58% | -74.32% | -60.16% | 75.95% |
Correlation
The correlation between RGEN and AMLX is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Jan 7, 2022 | 0.26 |
Fundamentals
RGEN:
$7.84B
AMLX:
$1.88B
RGEN:
$0.91
AMLX:
-$1.55
RGEN:
3.72
AMLX:
6.88
RGEN:
$763.34M
AMLX:
$0.00
RGEN:
$285.10M
AMLX:
-$20.10M
RGEN:
$156.19M
AMLX:
-$150.30M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RGEN vs. AMLX — Risk / Return Rank
RGEN
AMLX
RGEN vs. AMLX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Repligen Corporation (RGEN) and Amylyx Pharmaceuticals, Inc. (AMLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RGEN | AMLX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.43 | ||
| Sortino ratioReturn per unit of downside risk | -2.49 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.37 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 5.43 | -5.13 |
| Martin ratioReturn relative to average drawdown | 0.65 | 11.63 | -10.98 |
Loading charts...
Drawdowns
RGEN vs. AMLX - Drawdown Comparison
The maximum RGEN drawdown since its inception was -98.28%, roughly equal to the maximum AMLX drawdown of -96.04%. Use the drawdown chart below to compare losses from any high point for RGEN and AMLX.
Loading charts...
Drawdown Indicators
| RGEN | AMLX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.28% | -96.04% | -2.24% |
Max Drawdown (1Y)Largest decline over 1 year | -40.28% | -30.61% | -9.67% |
Max Drawdown (3Y)Largest decline over 3 years | -50.64% | -93.09% | +42.45% |
Max Drawdown (5Y)Largest decline over 5 years | -68.27% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -68.27% | — | — |
Current DrawdownCurrent decline from peak | -57.31% | -58.47% | +1.16% |
Average DrawdownAverage peak-to-trough decline | -63.35% | -59.40% | -3.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.93% | 14.27% | +4.66% |
Volatility
RGEN vs. AMLX - Volatility Comparison
The current volatility for Repligen Corporation (RGEN) is 15.07%, while Amylyx Pharmaceuticals, Inc. (AMLX) has a volatility of 16.24%. This indicates that RGEN experiences smaller price fluctuations and is considered to be less risky than AMLX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RGEN | AMLX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.07% | 16.24% | -1.17% |
Volatility (6M)Calculated over the trailing 6-month period | 32.57% | 43.35% | -10.78% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.62% | 67.33% | -21.71% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.62% | 91.40% | -40.78% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 45.85% | 91.40% | -45.55% |
Dividends
RGEN vs. AMLX - Dividend Comparison
Neither RGEN nor AMLX has paid dividends to shareholders.
Financials
RGEN vs. AMLX - Financials Comparison
This section allows you to compare key financial metrics between Repligen Corporation and Amylyx Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
RGEN and AMLX have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AMLX has higher volatility (16.24%) compared to RGEN (15.07%). In terms of maximum drawdown, RGEN dropped -98.28% vs AMLX's -96.04%.
AMLX currently has the higher Sharpe Ratio (2.70 vs 0.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RGEN and AMLX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer